Drug Search Results
More Filters [+]

PG-11047

Alternative Names: pg-11047, pg11047, pg 11047
Latest Update: 2022-04-10
Latest Update Note: PubMed Publication

Product Description

PG11047 is a novel conformationally restricted analog of the natural polyamine spermine that lowers cellular endogenous polyamine levels and competitively inhibits natural polyamine functions leading to cancer cell growth inhibition. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3115432/)

Mechanisms of Action: PT Analogue

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Progen
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PG-11047

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified|Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00705653

P1

Completed

Oncology Solid Tumor Unspecified

2009-08-01

PROGEN-SL002

P1

Completed

Lymphoma

2008-09-01

Recent News Events